Playback speed
10 seconds
Pulmonary Hypertension in Patients With ILD: Who, Why and How?
782 views
April 10, 2023
This webcast series includes repurposed education from Cleveland Clinic's Pulmonary Hypertension Summit 2022. This educational ...
read more ↘ activity will keep clinicians updated on the advances in the diagnosis and treatment of PH. The Activity Director and presenters, all renowned experts in Pulmonary Hypertension, have identified the following topics as having knowledge, competency, and practice gaps among clinicians:
Advances in the diagnostic and hemodynamic evaluation of PH.
Risk stratification and treatment algorithms.
Emerging therapies.
PH in patients with heart failure with preserved ejection fraction.
PH in patients with interstitial lung disease.
Chronic thromboembolic PH.
Pulmonary vascular limitation in patients who survive COVID-19.
Pulmonary hypertension through pulmonary vascular disease phenomics (PVDOMICs).
Heterogeneity of metabolic endo-phenotypes of PAH.
Metabolic interventions in PAH.
PAH single-cell omics atlas.
↖ read less
read more ↘ activity will keep clinicians updated on the advances in the diagnosis and treatment of PH. The Activity Director and presenters, all renowned experts in Pulmonary Hypertension, have identified the following topics as having knowledge, competency, and practice gaps among clinicians:
Advances in the diagnostic and hemodynamic evaluation of PH.
Risk stratification and treatment algorithms.
Emerging therapies.
PH in patients with heart failure with preserved ejection fraction.
PH in patients with interstitial lung disease.
Chronic thromboembolic PH.
Pulmonary vascular limitation in patients who survive COVID-19.
Pulmonary hypertension through pulmonary vascular disease phenomics (PVDOMICs).
Heterogeneity of metabolic endo-phenotypes of PAH.
Metabolic interventions in PAH.
PAH single-cell omics atlas.
↖ read less
Comments 1
Login to view comments.
Click here to Login